Investor Relations
Press Releases
2009
December 11, 2009:
iCo Therapeutics Provides Phase 1 DME Clinical Trial Update and Phase 2 Trial Guidance
November 20, 2009:
iCo Therapeutics Completes Final Tranche of $4,000,000 Brokered Private Placement
October 30, 2009:
iCo Therapeutics Completes First Tranche of Brokered Private Placement
October 20, 2009:
iCo Therapeutics Announces $4,000,000 Brokered Private Placement
September 24, 2009:
iCo Therapeutics Signs Collaboration Agreement with The Consortium for Parasitic Drug Development
August 24, 2009:
iCo Therapeutics Q2 2009 Financial Results
July 21, 2009:
iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board
July 16, 2009:
iCo Therapeutics Closes Non-Brokered Private Placement
July 7, 2009:
iCo Therapeutics Diabetic Macular Edema Clinical Trial Update
July 2, 2009:
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
June 25, 2009:
iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases
June 8, 2009:
Shareholders Approve All Resolutions at iCo Therapeutics Annual General Meeting
May 29, 2009:
iCo Therapeutics Q1 2009 Financial Results
April 30, 2009:
iCo Therapeutics Year-End 2008 Financial Results
April 29, 2009:
iCo Therapeutics to Present at BioFinance 2009
March 23, 2009:
iCo Therapeutics Oral Anti-Parasitic Drug to be Presented at Global Health Symposia
March 17, 2009:
iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference
February 20, 2009:
iCo Therapeutics Grants Options to New Directors
February 19, 2009:
iCo Therapeutics iCo-007 Results to be Presented at Prestigious Ocular Conference
February 18, 2009:
iCo Therapeutics Oral Amphotericin B Published in Leading Journal
February 9, 2009:
iCo Therapeutics Closes $1.3 Million Private Placement
January 30, 2009:
iCo Therapeutics Closes First Tranche of Non-Brokered Private Placement
2008
November 18, 2008:
iCo Therapeutics Oral Amphotericin B Poster at AAPS
November 17, 2008:
iCo Therapeutics Third Quarter Financial Results
November 7, 2008:
iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis
October 9, 2008:
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results
October 1, 2008:
iCo Therapeutics Selected as Canada’s Top 10™ Competition Winner
September 29, 2008:
iCo Therapeutics to Present at BioContact Québec
September 22, 2008:
iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)
September 4, 2008:
iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial
August 28, 2008:
iCo Therapeutics Second Quarter Financial Results
July 8, 2008:
iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board
June 26, 2008:
iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
June 9, 2008:
iCo Therapeutics Closes $1,140,450 Financing
June 2, 2008:
iCo Therapeutics Announces $1,140,450 Financing
May 30, 2008:
iCo Therapeutics First Quarter Financial Results
May 7, 2008:
iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)
May 5, 2008:
iCo Therapeutics to Present at BioFinance 2008
April 28, 2008:
iCo Therapeutics Year-End 2007 Financial Results
April 25, 2008:
iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO
April 21, 2008:
iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting
March 17, 2008:
iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
March 10, 2008:
iCo Therapeutics Provides iCo-008 Phase II Clinical Update
February 27, 2008:
iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference
January 21, 2008:
iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update
2007
December 31, 2007:
iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement
October 31, 2007:
Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
October 16, 2007:
Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.
October 9, 2007:
Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
January 22, 2007:
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
January 10, 2007:
iCo Therapeutics announces licensing deal
iCo Therapeutics has announced a licensing deal that gives it worldwide rights for the development and commercialization of CAT-213, a treatment for allergic disorders.
January 8, 2007:
Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo
Cambridge Antibody Technology licenses monoclonal antibody (CAT-213) for treatment of allergy disorders to iCo Therapeutics
View Press Releases Archive >
